SelSA

Overview

SelSA is a selective, orally active inhibitor for histone deacetylase 6 ( HDAC6 ) with IC 50 of 56.9 nM. SelSA inhibits the phosphorylation of ERK1/2. SelSA inhibits the proliferation of breast cancer cells and hepatocellular carcinoma cells with IC 50 of 0.58-2.6 μM, inhibits cell migration and invasion of Huh7, and induces apoptosis . SelSA exhibits antitumor activity in mouse model.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-162616
• CAS No.: 1225038-92-5
• Molecular Formula: C13H16N2OSe
• Molecular Weight: 295.24
• Purity: 99.83%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (8.47 mM); Clear solution
• Availability: In-stock

Source

Original product source